The influence of enteral feedings (with Ensure) on the absorption of phenytoin sodium from capsules was studied. Six healthy adult volunteers were given a single dose of phenytoin capsules 400 mg po on two occasions. Blood specimens were collected for 48 hours after each dose. In a randomized, crossover fashion, each subject completed the following two phases: (1) phenytoin without enteral feedings, and (2) concomitant enteral feedings before phenytoin and continued at 100 ml/h for ten hours. The areas under the concentration versus time curves from 0-48 hours (AUCo-48) were not significantly different between the two phases (p > 0.5). The percent relative bioavailability of phenytoin with enteral feedings was 101.7 percent. This study suggests that enteral feedings do not affect the serum concentrations of phenytoin after a single dose given in capsule form.
Get full access to this article
View all access options for this article.
References
1.
OlanowCW, FinnAL. Phenytoin: pharmacokinetics and clinical therapeutics.Neurosurgery1981; 8: 1127.
2.
RallTW, SchleiferLS. Drugs effective in the therapy of the epilepsies. In: GilmanAG, GoodmanLS, RallTW, MuradF ed. Goodman and Gilman's the pharmacological basis of therapeutics.7th ed.New York: Macmillan, 1985: 44672.
3.
BuchthalF, SvensmarkO, SchillerPJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin.Arch Neurol1960; 2: 62430.
4.
LascellesPT, KocenRS, ReynoldsEH. The distribution of plasma Phenytoin levels in epileptic patients.J Neurol Neurosurg Psychiat1970; 33: 5015.
5.
TozerTN, WinterME. Phenytoin. In: EvansWE, SchentagJJ, JuskoWJ eds. Applied pharmacokinetics: principles of therapeutic drug monitoring.San Francisco: Applied Therapeutics, 1980: 275318.
6.
RichensA. Clinical pharmacokinetics of Phenytoin.Clin Pharmacokinet1979; 4: 15369.
7.
RichensAM, DunlopA. Serum Phenytoin levels in management of epilepsy.Lancet1975; 2: 2478.
NeuvonenPJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.Clin Pharmacokinet1979; 4: 91103.
10.
KulshresthaVK, ThomasM, WadsworthJ, RichensA. Interaction between phenytoin and antacids.Br J Clin Pharmacol1978; 6: 1779.
11.
O'BRIENLS, OrmeMLE, BreckenridgeAM. Failure of antacid to alter the pharmacokinetics of phenytoin.Br J Clin Pharmacol1978; 6: 1767.
12.
PeruccaE, RichensA. Drug interactions with phenytoin.Drugs1981; 21: 12037.
13.
CarterBL, GarnettWR, PellockJM, StrattonMA, HowellJR. Effect of antacids on phenytoin bioavailability.Ther Drug Monit1981; 3: 33340.
14.
McelnayJC, UprichardG, CollierPS. The effect of activated dimethicone and proprietary antacid preparation containing this agent on the absorption of phenytoin.Br J Clin Pharmacol1982; 13: 5015.
15.
YuenGJ. Agents affecting phenytoin bioavailability.Drug Int Newsl1984; 4(10): 3742.
16.
SmartHL, SomervilleKW, WilliamsJ, RichensA, LangmanJS. The effects of sucralfate upon phenytoin absorption in man.Br J Clin Pharmacol1985; 20: 23840.
17.
HallTG, CuddyPG, GlassCJ, MelethilS. Effect of sucralfate on phenytoin bioavailability.Drug Intell Clin Pharm1986; 20: 60711.
18.
HerishanuY, EylathU, IlanR. Effect of calcium content of diet on absorption of diphenylhydantoin.Israel J Med Lci1976; 12: 14536.
19.
MelanderA, BranteG, JohanssonO, LindbergT, Wahlin-BollE. Influence of food on the absorption of phenytoin in man.Eur J Clin Pharmacol1979; 15: 26974.
20.
KennedyMC, WadeDN. The effect of food on the absorption of phenytoin.Aust N Z J Med1982; 12: 25861.
21.
BauerLA. Interference of oral phenytoin absorption by continuous nasogastric feedings.Neurology (NY)1982; 32: 5702.
22.
OzunaJ, FrielP. Effect of enteral tube feeding on serum phenytoin levels.J Neurosurg Nurs1984; 16: 28991.
